Medical researchers have demonstrated that lutetium-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy of patients with metastatic castration-resistant prostate cancer.
Medical researchers have demonstrated that lutetium-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy of patients with metastatic castration-resistant prostate cancer.